Objectives
The cost per responder (CPR) analysis is a way to evaluate and compare the costs and effectiveness of different treatments. Currently these studies are not available in Colombia that estimate CPR for plaque psoriasis treatments. The aim of this study was to estimate CPR for the treatment of moderate to severe plaque psoriasis for biological therapies approved by the Colombian regulatory agency, who achieved reductions of 75% and 90% in the Psoriasis Area and Severity Index (PASI75/90) for each treatment.
Methods
The annual cost per responder achieving a PASI75 or a PASI90 for a set of biological treatments was calculated based on the number needed to treat (NNT) concept. This analysis was based on the estimates of a network meta-analysis of the NNT for each treatment and associated costs during the maintenance phase in Colombia. The costs included the acquisition, administration, and the monitoring of each therapy using official sources.
Results
In 2018, the annual cost in COP and USD ($ 3,099.3 COP = $1 USD) per respondent patient achieving a PASI75 was $ 25,117,108 ($ 8,104) for infliximab, $ 39,058,590 ($ 12,602) for ixekizumab, $ 47,059,845 ($ 15,184) for secukinumab, $ 50,380,665 ($ 16,255) for adalimumab, $ 56,987,252 ($ 18,387) for ustekinumab and $ 65,352,869 ($ 21,086) for etanercept. For PASI90 costs per responder was $ 36,483,975 ($ 11,772) for infliximab, $ 47,995,725 ($ 15,486) for ixekizumab, $ 63,840,875 ($ 20,598) for secukinumab, $ 77,613,457 ($ 25,042) for adalimumab, $ 92,333,775 ($ 29,792) for ustekinumab and $ 132,158,023 ($ 42,641) for etanercept.
Conclusions
The application of CPR analysis of biologics to treat plaque psoriasis demonstrated that infliximab and Ixekizumab had the lowest cost per responder.
Article info
Identification
Copyright
© 2019 Published by Elsevier Inc.
User license
Elsevier user license | How you can reuse 
Elsevier's open access license policy
Elsevier user license
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy
